Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 6, Issue 8, Pages 617-635Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd2193
Keywords
-
Funding
- NHLBI NIH HHS [P01-HL-077180, P01-HL-59408] Funding Source: Medline
Ask authors/readers for more resources
Pathological stress from cardiovascular disease stimulates hypertrophy of heart cells, which increases the risk of cardiac morbidity and mortality. Recent evidence has indicated that inhibiting such hypertrophy could be beneficial, encouraging drug discovery and development efforts for agents that could achieve this goal. Most existing therapies that have antihypertrophic effects target outside-in signalling in cardiac cells, but their effectiveness seems limited, and so attention has recently turned to the potential of targeting intracellular signalling pathways. Here, we focus on new developments with small-molecule inhibitors of cardiac hypertrophy, summarizing both agents that have been in or are poised for clinical testing, and pathways that offer further promising potential therapeutic targets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available